Return to Publications
June 2017
The latest news on research, treatment, prevention and education from the state's only National Cancer Institute-designated Comprehensive Cancer Center
Bruce G. Haffty, MD

Three-Week Radiation Therapy Treatment Given Post Mastectomy is Safe and Effective

A shorter course of radiation therapy given to breast cancer patients following mastectomy is safe and effective and cuts treatment time in half. That is according to data from a phase II clinical trial conducted by Bruce G. Haffty, MD, professor and chair, Department of Radiation Oncology at Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School and Rutgers New Jersey Medical School, and colleagues who examined a hypofractionated therapy regimen. The work appeared in the May online edition of the Journal of Clinical Oncology.

nursing award winners

Rutgers Cancer Institute of New Jersey Nurses Celebrated for Leadership and Dedication

From patient care and research to peer mentoring and more, nurses at Rutgers Cancer Institute of New Jersey are involved in many aspects of oncology nursing that help advance the field. To recognize the scope of their work, they were celebrated during Oncology Nursing Month in May with the Oncology Nursing Excellence Awards given during the annual Elizabeth Gibby Osborne Lecture.

Exploring New Treatment Options for Pediatric Patients with Hodgkin Lymphoma

While gemcitabine and brentuximab vedotin each have benefit when given individually in the treatment of Hodgkin lymphoma, investigators from the Children's Oncology Group including Richard Drachtman, MD, clinical section chief of pediatric hematology-oncology at Rutgers Cancer Institute of New Jersey and professor of pediatrics at Rutgers Robert Wood Johnson Medical School, examined the two therapies when combined in pediatric patients. They found the combination to be safe and to have a greater complete response rate than when the drugs are given individually. Results will be presented at the American Society of Clinical Oncology Annual Meeting this month.

Issac Kim, MD, PhD

Surgery to Remove the Prostate and Metastatic Prostate Cancer is Safe and Feasible

An interim analysis of a phase I clinical trial examining a surgical procedure to remove the prostate and prostate cancer in men whose disease has spread (metastatic) shows the operation is safe and feasible in carefully selected patients. Isaac Yi Kim, MD, PhD, chief of urologic oncology at Rutgers Cancer Institute of New Jersey and associate professor of surgery at Rutgers Robert Wood Johnson Medical School, and colleagues presented the results last month at the Annual Meeting of the American Urological Association.

Darren Carpizo, MD, PhD

Long Term Survival Indicated for Stage IV Colorectal Cancer Patients who Live at Least Two Years

Research has shown that improvements in chemotherapy and liver surgery have resulted in increased overall survival in patients with advanced stage colorectal cancer. To better predict outcomes for these patients, Darren Carpizo, MD, PhD, director of the Hepatobiliary Oncology Program at Rutgers Cancer Institute of New Jersey and associate professor of surgery and pharmacology at Rutgers Robert Wood Johnson Medical School, and colleagues conducted a retrospective analysis. Results to be presented at the American Society of Clinical Oncology Annual Meeting this month show stage IV colorectal cancer patients who survive at least two years have a better prognosis than originally thought.